Perrigo Company plc

PRGO

IE00BGH1M568

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:00:01 16/05/2024 am IST			5-day change	1st Jan Change
30.21 ^USD	-0.26%		-2.80%	-6.03%

07/05	Perrigo's Q1 Adjusted Earnings, Net Sales Drop	MT
07/05	Transcript : Perrigo Company plc, Q1 2024 Earnings Call, May 07, 2024

Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024

May 01, 2024 at 07:12 pm IST

Perrigo Company plc announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024.

Latest news about Perrigo Company plc

Perrigo's Q1 Adjusted Earnings, Net Sales Drop	07/05	MT
Transcript : Perrigo Company plc, Q1 2024 Earnings Call, May 07, 2024	07/05
Earnings Flash (PRGO) PERRIGO COMPANY Posts Q1 Revenue $1.08B	07/05	MT
Earnings Flash (PRGO) PERRIGO COMPANY Posts Q1 EPS $0.29, vs. Street Est of $0.23	07/05	MT
Perrigo Company plc Reports Earnings Results for the First Quarter Ended March 30, 2024	07/05	CI
Perrigo Company plc Reaffirms Earnings Guidance for 2024	07/05	CI
Perrigo Announces Executive Transition for Its Consumer Self-Care International Business	07/05	CI
Perrigo Keeps Quarterly Dividend at $0.276 Per Share; Payable June 18 to Shareholders on May 31	02/05	MT
Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024	01/05	CI
Sector Update: Health Care Stocks Decline Late Afternoon	26/04	MT
Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million	25/04	MT
Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc for approximately ?280 million.	25/04	CI
Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating	08/04	MT
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors	05/04	RE
Multiple CVS Caremark Plans to Cover Perrigo's Opill at No Cost	05/04	MT
Multiple CVS Caremark Plans Reportedly to Cover Perrigo's Opill at No Cost	05/04	MT
Sector Update: Health Care Stocks Rise Late Afternoon	20/03	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	20/03	MT
Perrigo Shares Rise After Wisconsin Governor Makes Birth Control Pill Free for Medicaid Members	19/03	MT
Transcript : Perrigo Company plc Presents at UBS Global Consumer and Retail Conference 2024, Mar-13-2024 04:00 PM	14/03
Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors	07/03	CI
Perrigo Company plc Commences Shipments of Opill to Retailers Nationwide, Empowering Millions to Enter A New Era of Reproductive Health Access in the United States	04/03	CI
Perrigo Co Insider Bought Shares Worth $252,168, According to a Recent SEC Filing	01/03	MT
JPMorgan Cuts Price Target on Perrigo to $41 From $48, Maintains Overweight Rating	28/02	MT
Perrigo Company plc Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI

Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.

Sector

Pharmaceuticals

Calendar

31/05/2024 - Ex-dividend day

More about the company

Income Statement Evolution

More financial data

Ratings for Perrigo Company plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30.29 USD

Average target price

39.5 USD

Spread / Average Target

+30.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PERRIGO COMPANY PLC	-6.03%	412.91Cr
NOVO NORDISK A/S	+31.37%	59TCr
JOHNSON & JOHNSON	-2.78%	36TCr
MERCK & CO., INC.	+20.54%	33TCr
ABBVIE INC.	+5.57%	29TCr
ASTRAZENECA PLC	+14.83%	24TCr
NOVARTIS AG	+9.93%	21TCr
ROCHE HOLDING AG	-6.95%	20TCr
AMGEN INC.	+11.04%	17TCr
PFIZER, INC.	+0.27%	16TCr

Other Pharmaceuticals